N-Acetyl Selank Amidate
N-Acetyl-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2 (N-acetylated, C-terminal amidated analog of Selank/TP-7)
Investigational derivative of selank. Not FDA-approved or evaluated for compounding. Available as a research chemical.
A chemically stabilized version of Selank, an anti-anxiety peptide developed in Russia, modified to last longer in the body. No human trials exist for this specific form; its expected effects on anxiety and thinking ability are based on studies of the original Selank compound.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
N-Acetyl Selank Amidate is preclinical or hypothesis-only.
Investigational derivative of selank. Not FDA-approved or evaluated for compounding. Available as a research chemical.
Safety Summary
Safety data is primarily extrapolated from the parent compound Selank, not from direct NA-Selank-Amidate studies. Published Selank clinical trials (sample sizes ~60-70 patients, durations up to ~1 month) reported no treatment-related serious adverse events and no dose-limiting toxicities (PMID 25176261, PMID 26356395). No FAERS or EudraVigilance safety signals found for NA-Selank-Amidate as of March 2026. No chronic toxicology, carcinogenicity, reproductive toxicology, or organ-impairment studies have been published. Preclinical rodent data for Selank show no tolerance, tachyphylaxis, withdrawal effects, or dependence signals (PMC5322660; PMID 24913576). The absence of long-term safety data should NOT be interpreted as evidence of absence of risk.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Cited sources
Every claim on this page links to one of the 11 sources below. Identifiers are PubMed (PMID), ClinicalTrials.gov (NCT), or DOI; click through to the source of record before acting on a claim.
- 1PMID 18454096PubMed
- 2PMID 26356395PubMed
- 3PMID 25176261PubMed
- 4doi:10.3389/fphar.2016.00031DOI
- 5doi:10.1134/S1819712423020174DOI
- 6doi:10.1155/2017/5091027DOI
- 7PMID 24913576PubMed
- 8Semax and Selank Inhibit the Enkephalin-Degrading Enzymes of Human SerumReference
- 9PMID 15835541PubMed
- 10PMID 16193654PubMed
- 11Immunomodulatory effects of selank in patients with anxiety-asthenic disordersReference